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eveloping resistance to drugs against MRSA
. Gould
Aberdeen Royal Inﬁrmary, Aberdeen, Saudi Arabia
Across the world, vancomycin has shown a surprising resilience
o being displaced as the ﬁrst choice treatment for serious MRSA
nfection. With the ﬁrst description of low level resistance (VISA
nd hVISA in the late 1990s) an urgency to develop new MRSA
rugs developed, further stimulated by the emergence of high level
ancomycin resistance in the early 2000s. High level resistance
asn’t become a clinical problem yet and VISA has, arguably, not
merged as a signiﬁcant problem either. What is much more sig-
iﬁcant numerically, and probably even clinically are hVISA and
o-called MIC creep or leap, with vancomycin MICs elevated above
ild-type values but still within internationally accepted break-
oints (BPs). A growingbodyof published studies now identify such
trains as the norm and also that clinical response in serious infec-
ion is impaired. It has to be accepted, however, that this is a very
ontroversial area.MIC testing systems are at their limit of sensitiv-
ty and there is little clinical evidence that increasing vancomycin
ose to improve PK/PD target attainment has any beneﬁcial effect.
ancomycin is however, perceived by many to be at the end of
ts useful life for treating serious infections. Its therapeutic ratio is
ow just too narrow. Recent IDSA guidelines fail to acknowledge
his situation, however.
Newdrugs such as linezolid and daptomycin aremaking signiﬁ-
ant inroads into clinical use but both are troubled by early reports
f resistance, some of it plasmid mediated. Old drugs too are also
eing used increasingly, but resistance is an emerging issue here
oo.
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esistance to agents for MRSA decolonization and its clinical
mplications
. Apisarnthanarak
Thammasat University Hospital, Pratumthani, Thailand
In most parts of the world, methicillin-resistant Staphylococ-
us aureus (MRSA) infection have continued to increase despite
ntensive infection-control efforts. Some groups have advocated
searchanddestroy”policies that recommend routine screening for
RSA to identify, isolate, and treat carriers, with the ultimate goal
f eradicating the pathogen from health care facilities. All MRSA
arriers are not the same; carriage may be transient, intermit-
ent, or persistent for months to years. Persistent carriers are morenfectious Diseases 16S (2012) e2–e157
heavily colonized (frequently at multiple sites), are more likely to
transmit to others, and are more likely to become infected than
transient carriers. Methods to eradicate MRSA have included the
use of oral antibiotics plus rifampin. The use of rifampin ensures
excellent penetration into secretions and tissues. The use of com-
bination therapy has been effective in treating MRSA in the nares
and at other sites. However, the wide-scale use of systemic antibi-
otics has been associated with the development of drug resistance
and the loss of valuable therapeutic agents for subsequent treat-
ment of infection. As a result of this drug-resistance issue, topical
antibacterial agents and germicides have been the preferred inter-
vention for MRSA eradication programs. Therefore, chlorhexidine
and/or mupirocin to decolonize patients. Increased mupirocin use
has been associated with increased drug resistance and failure to
clear the organism. The gene for high-level mupirocin resistance,
mupA, suggesting that the future usefulness of this drug might lim-
ited. Increased resistance ofMRSA to systemic antibiotics following
decolonization regimens has also been an issue in this study and
others. Resistance to other germicides in MRSA has been reported
following wide-scale use; whether resistance to chlorhexidine and
its clinical implications will become an issue is not yet known. In
this presentation, I will discuss decolonization strategy, resistant
to agents for MRSA decolonization and its clinical implications.
http://dx.doi.org/10.1016/j.ijid.2012.05.134
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PK/PD considerations when treating MRSA
T. Mazzei
University of Florence, Florence, Italy
Treatment of MRSA infections may often represent a life-
threatening challenge and clinicians should be conﬁdent and apply
the most advanced pharmacokinetic/pharmacodynamic (PK/PD)
knowledge. There are in fact extensive data showing that the
administration of antimicrobials according to PK/PD parameters
improves the possibility of a positive clinical outcome, particularly
in severely ill patients.
The three main PK/PD parameters able to predict antimicrobial
efﬁcacy are the maximum concentration (Cmax)/minimum
inhibitory concentration (MIC) ratio, the area under the
concentration-time curve (AUC/MIC) ratio and the time dur-
ing which the drug concentration exceeds the MIC (T>MIC). The
relative importance of the three PK/PDparameters varies according
to different antimicrobial classes, and sometimes overlaps.
Moreover, critically ill patients require great attention in terms
ofdosages, posologyandadministration routeof antimicrobialsdue
to the many pathophysiological changes occurring during a severe
acute illness or sepsis (i.e. increased capillary permeability, third
spacing, increase of volume of distribution, variation of renal or
liver function). All these factors may affect a drug’s pharmacoki-
netics, especially the hydrophilic, renally excreted antibacterials
(e.g. b-lactams, aminoglycosides and glycopeptides). Therefore, the
serum and tissue concentrations achieved when these drugs are
administered at dosages suggested for healthy volunteers are often
suboptimal. The pharmacological strategies to be used in these
patients are, for example, to increase doses and/or time of infusion
al of I
f
d
s
t
t
t
T
f
p
a
a
s
i
o
m
n
a
b
d
h
T
F
S
D
T
R
E
a
K
b
c
t
b
g
a
T
i
i
a
a
i
i
m
c
(
N
o
m
s
a
e
i
i15th ICID Abstracts / International Journ
or many betalactams and probably for linezolid, that are time-
ependent drugs.
For both glycopeptides (teicoplanin and vancomycin), several
tudies have emphasized the role of the AUC/MIC ratios predic-
ive of efﬁcacy. In the ICU setting appropriate loading doses of
eicoplanin to ensure rapid, therapeutically effective concentra-
ions and to avoid the risk of underexposure must be considered.
herapeutic drug monitoring (TDM) is strongly recommended
or vancomycin, with the aim of optimizing drug exposure and
reventing toxicity in the individual patient. Daptomycin, char-
cterized by a rapid concentration-dependent effect, is currently
pproved by the US FDA and European EMA forS. aureusblood-
tream infections at dosages of 6 mg/kg once daily. However, there
s a tendency to use daptomycin at higher doses, with the aim of
btaining more rapid bacteriological and clinical efﬁcacy.
This presentation will summarize the most signiﬁcant experi-
ental and clinical data on the optimization of the use of old and
ew antimicrobials for MRSA according to PK/PD parameters, in
n effort to improve patient care by achieving optimal antimicro-
ial exposure and limit the development of resistance to available
rugs.
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ncephalitis: Laboratory perspectives of challenges to establish
etiology
.-B. Chua
National University of Singapore, Singapore, Singapore
Encephalitis is very broadly deﬁned as an inﬂammation of the
rain parenchyma, but most commonly addresses infections of the
entral nervous system with involvement of brain. The inﬂamma-
ory process can affect any of the brain structures, namely, neurons,
lood vessel, glial cells or a combination of any of the three.
Encephalitis is a “syndrome” of multiple aetiologies and patho-
enesis. A large number of both infectious and non-infectious
etiologies are attributed to cause inﬂammationof brain structures.
he infectious pathogens can range from the relatively “simplistic”
nfectious proteins and viruses to more organised complex organ-
sms such as bacteria, fungi and parasites. In addition, infectious
gents can cause inﬂammation by directly infecting or indirectly
ffecting brain structures. Compounded to this complex situation,
nﬂammation of brain parenchyma can be immune-mediated lead-
ng to clinical manifestation of encephalitic syndrome. Though
ore than 100 pathogens have been identiﬁed to be able to
ause infectious encephalitis and a growing number of antibodies
inclusive of newly described voltage-gated potassiumchannel and
-methyl-D-aspartate receptor) have been implicated as causes
f immune-mediated encephalitis, the aetiology of up to 50% or
ore cases of encephalitis remained unexplained in a number of
ystematic prospective studies using an expanded testing battery
ndapplying latest powerfulmolecular biological techniques. Thus,
stablishing the aetiology of encephalitis, especially if it is of an
ndividual case, can be a daunting task for diagnostic microbiolog-
cal laboratory.nfectious Diseases 16S (2012) e2–e157 e55
Based on past experiences, the challenges face by diagnos-
tic laboratories to establish the aetiologies of encephalitis in a
timely manner for effective patient’s management and/or out-
break control can generally be divided into two broad categories,
ex-laboratory and intra-laboratory. The challenges pose by ex-
laboratory factors vary fromcountry to countrywhich are normally
notwithin the control of laboratory yet are crucial for achieving lab-
oratory diagnosis of correct aetiologies. The ex-laboratory factors
ranges from country’s in-place policy and resources, adequacy of
accurate clinical, epidemiological, autopsy/histopathological, and
ancillary clinical diagnostic laboratory data, communication and
networking, quality and quantity of clinical samples. The above fac-
tors are critical in guiding the laboratory inprioritizationandchoice
of the battery of laboratory tests, the extent and depth of testing,
and timely referral if appropriate, for achieving timely, accurate
and cost-effective laboratory results. The basis and importance
of ancillary laboratory information, such as neuroimaging, in the
investigation of patient with clinical manifestation of encephalitic
syndrome will be covered in depth by the second speakers. The
third speaker will elaborate the importance of clinical, epidemio-
logical and ancillary laboratory (EEG, CSF ﬁndings) information in
guiding the diagnostic laboratory besides focusing on epidemiol-
ogy, disease burden and aetiologies of encephalitis with speciﬁc
reference to the experiences in Thailand.
Intra-laboratory challenges include an in-placed integrated and
co-ordinated country’s public health laboratory system, establish-
ment and sustainability of required battery of laboratory tests,
functional laboratory communication and networking, interpre-
tation of laboratory output results. The challenges and need to
establish an integrated functional public health laboratory system
and range of laboratory tests to diagnose known and poten-
tially novel emerging pathogens causing encephalitis will be
presented. The presentation will emphasize the need for a har-
monious and coherent team consisting of public health specialist,
physician and laboratory medicine personnel to overcome chal-
lenges in establishing accurate laboratory diagnosis of patients
having encephalitis especially in an outbreak situation due to a
novel pathogen. Illustration on the need for team approach and
challenges encountered to establish the accurate aetiologies of out-
breaks of hand foot andmouthdiseasewith fatal encephalomyelitis
amongst children in 1997 and fatal febrile encephalitis among pig-
farm workers in 1998/99 in Malaysia will be brieﬂy presented.
http://dx.doi.org/10.1016/j.ijid.2012.05.136
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Encephalitis: Does neuroimaging help?
J. Laothamatas
Ramathibodi Hospital, Bangkok, Thailand
MRI is the main modality in encephalitis investigation with
CT as a supplementary technique. MRI provides both conven-
tional anatomical-based and advanced molecular, biochemical
and perfusion-based information. The anatomical-based informa-
tion such as T1W, T2W, FLAIR and gradient pulse sequences
allows us to detect the abnormality and offers the data on the
location/distribution and associated hemorrhage. It also provides
